

Mark Wade
wade@salk.edu
Curriculum Vitae

Education

- 1997-2001:** Doctor of Philosophy, Imperial College, London, UK: Virology and Cell Biology.
Supervisor: Professor Martin J. Allday.
Thesis topic: Genotoxin-induced apoptosis in human B cells
- 1993-1997:** Bachelor of Science (First Class, Honors) Molecular and Cellular Biology. University of Bath, UK.

Publications

Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL Wahl GM and Walensky LD (2010). A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53. *Cancer Cell* (Manuscript accepted for publication August 2010).

Wade M, Wang YV and Wahl GM (2010). The p53 orchestra: mdm2 and mdmx set the tone. *Trends in Cell Biology* 20(5):299-309.

Wang YV, Wade M and Wahl GM (2009). Guarding the Guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo. *Cell Cycle* 6;8(21).

Wang YV, LeBlanc M, Wade M, Jochemsen A and Wahl GM (2009). Increased radio-resistance and accelerated B-cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA damage-activated kinases. *Cancer Cell* Jul 7;16(1):33-43

Wade M and Wahl GM (2009). Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? *Mol Cancer Res* 7: 1-11

Wade M, Rodewald LW, Espinosa JM and Wahl GM (2008). BH3 activation blocks Hdmx suppression of apoptosis and co-operates with Nutlin to induce cell death. *Cell Cycle* July 1;7;(13):1973-82.

Wang Y, Wade M, Wong ET, Li YC, Rodewald LW, and Wahl GM (2007). Quantitative analyses reveal the importance of regulated Hdmx degradation for P53 activation *PNAS* Jul 24;104(30):12365-70

Leao M, Anderton E, Wade M, Meekings K, and Allday MJ (2006). Epstein-Barr virus (EBV)-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. *J. Virol.* 2007 Jan;81(1):248-60. Epub 2006 Oct 11

Wade M, Wong ET, Tang M, Stommel JM and Wahl GM (2006). Hdmx modulates the outcome of p53 activation in human tumor cells. *J Biol Chem* Nov 3;281(44):33036-44. Epub Aug 13.

Wade M and Wahl GM (2006). c-Myc, Genome Instability, and Tumorigenesis: The Devil is in the Details. In "The Myc/Max/Mad Transcription Factor Network". Editor Robert Eisenman. *Current Topics in Microbiology and Immunology* Vol 302. pp169-203. Publisher: Springer-Verlag.

Wahl GM, Stommel JM, Krummel KA and Wade M (2005) Gatekeepers of the guardian: p53 regulation by post-translational modification, mdm2 and mdmx. In "25 Years of p53 Research". Chapter 4:73-113. Editors: Klas Wimman and Pierre Hainaut. Publisher: Springer-Verlag

Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. *Mol Cell* 9(5):1031-44.

Wade M and Allday MJ (2000). Epstein-Barr virus abrogates a G2/M checkpoint activated by genotoxins. *Mol Cell Biol*. 2000 Feb;20(4):1344-60.

Walsh DA, Wade M, Mapp PI and Blake DR (1998). Focally regulated endothelial proliferation and cell death in human synovium. *Am J Pathol* 152(3):691-702

Grants awarded

Co-author on R03 grant MH089489-01 "High throughput screen for inhibitors of the mdm2/mdmx interaction" from the National Institutes of Health under the roadmap initiative.

Awards

First Prize for poster entitled "The Mdmx N terminus regulates Mdmx stability and p53 activity". Presented at the 5th Annual Mdm2 Workshop, Belgium Aug 23-26, 2009.

AACR Young Investigator Award. For "Modulation of p53-dependent apoptosis by Hdmx". Presented at the 4th Annual Mdm2 Workshop, Woods Hole, MA Sept 30-Oct3, 2007.

Invited talks

Hits and misses: targeting the mdmx oncogene for cancer therapy. International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, Sept 11, 2009.

Posters and presentations

BH3 activation overcomes Hdmx suppression of apoptosis and co-operates with Nutlin-3a to induce cell death. **AACR 99th Annual Meeting**, April 12-16th, 2008. San Diego, CA.

Hdm2 and Hdmx: Independent targets for p53 activation in cancer? (oral presentation). **3rd Tumor Progression and Therapeutic Resistance Meeting**. Baltimore, MD. 22-24 October 2006.

Activated c-myc sensitizes cells to small molecule inhibitors of the p53/hdm2 interaction (oral presentation). **4th Salk Institute Cell Cycle Meeting**, La Jolla, CA. 24-28 June 2005.

c-myc enhances the cytotoxicity of small molecule activators of p53. **Wade M**, Vassilev L and Wahl GM. **AACR 96th Annual Meeting**, April 16-20, 2005. Anaheim, CA.